WO2004098567A3 - Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer - Google Patents
Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer Download PDFInfo
- Publication number
- WO2004098567A3 WO2004098567A3 PCT/US2004/013810 US2004013810W WO2004098567A3 WO 2004098567 A3 WO2004098567 A3 WO 2004098567A3 US 2004013810 W US2004013810 W US 2004013810W WO 2004098567 A3 WO2004098567 A3 WO 2004098567A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active agent
- agent component
- dosage form
- tamper
- adverse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200501702A EA009623B1 (en) | 2003-04-30 | 2004-04-30 | Tamper-resistant transdermal dosage form |
JP2006514265A JP5048324B2 (en) | 2003-04-30 | 2004-04-30 | Tamper-resistant transdermal dosage form comprising an active substance element and a side-effect substance element distal to the active substance layer |
MXPA05011703A MXPA05011703A (en) | 2003-04-30 | 2004-04-30 | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer. |
CA2522529A CA2522529C (en) | 2003-04-30 | 2004-04-30 | Tamper resistant transdermal dosage form |
AU2004235794A AU2004235794B8 (en) | 2003-04-30 | 2004-04-30 | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
YUP-2005/0812A RS20050812A (en) | 2003-04-30 | 2004-04-30 | Tamper resistant transdermal dosage form |
MEP-2008-492A ME00276B (en) | 2003-04-30 | 2004-04-30 | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
NZ542969A NZ542969A (en) | 2003-04-30 | 2004-04-30 | Tamper resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
CN200480011691.XA CN1780611B (en) | 2003-04-30 | 2004-04-30 | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
EP04751268.6A EP1641441B1 (en) | 2003-04-30 | 2004-04-30 | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
KR1020057020592A KR101159828B1 (en) | 2003-04-30 | 2004-04-30 | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
BRPI0409945-1A BRPI0409945A (en) | 2003-04-30 | 2004-04-30 | change resistant dosage form |
IS8060A IS2935B (en) | 2003-04-30 | 2005-10-04 | Anti-doping dosage forms |
NO20054682A NO332157B1 (en) | 2003-04-30 | 2005-10-12 | Manipulation-safe transdermal dosage form comprising an active substance component and a counteracting drug component at the distal region of the active drug layer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46723503P | 2003-04-30 | 2003-04-30 | |
US46724303P | 2003-04-30 | 2003-04-30 | |
US60/467,235 | 2003-04-30 | ||
US60/467,243 | 2003-04-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004098567A2 WO2004098567A2 (en) | 2004-11-18 |
WO2004098567A3 true WO2004098567A3 (en) | 2005-01-13 |
Family
ID=33436723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/013810 WO2004098567A2 (en) | 2003-04-30 | 2004-04-30 | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
Country Status (22)
Country | Link |
---|---|
US (1) | US8778382B2 (en) |
EP (3) | EP2319505A1 (en) |
JP (1) | JP5048324B2 (en) |
KR (1) | KR101159828B1 (en) |
AR (1) | AR047936A1 (en) |
AU (1) | AU2004235794B8 (en) |
BR (1) | BRPI0409945A (en) |
CA (1) | CA2522529C (en) |
CL (1) | CL2004000927A1 (en) |
EA (1) | EA009623B1 (en) |
EC (1) | ECSP056191A (en) |
IS (1) | IS2935B (en) |
ME (1) | ME00276B (en) |
MX (1) | MXPA05011703A (en) |
MY (1) | MY141815A (en) |
NO (1) | NO332157B1 (en) |
NZ (1) | NZ542969A (en) |
PE (2) | PE20050146A1 (en) |
RS (1) | RS20050812A (en) |
TW (1) | TWI350186B (en) |
UA (1) | UA82880C2 (en) |
WO (1) | WO2004098567A2 (en) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US7182955B2 (en) * | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
US20040219195A1 (en) * | 2003-04-30 | 2004-11-04 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
CL2004000927A1 (en) | 2003-04-30 | 2005-01-28 | Purdue Pharma Lp | TRANSDERMAL DOSAGE FORM THAT INCLUDES AN ACTIVE AGENT, A NEXT SURFACE AND A DISTAL SURFACE. |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
LT2351555T (en) * | 2004-02-23 | 2016-12-27 | Euro-Celtique S.A. | Abuse resistance opioid transdermal delivery device |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102004039570B4 (en) * | 2004-08-14 | 2007-03-01 | Lts Lohmann Therapie-Systeme Ag | Monitoring system for collecting and transdermal further diffusion of environmental contaminants containing air and method thereto |
JP2008510713A (en) * | 2004-08-20 | 2008-04-10 | スリーエム イノベイティブ プロパティズ カンパニー | Transdermal drug delivery device with translucent protective film |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
TWI419717B (en) * | 2005-06-17 | 2013-12-21 | Altea Therapeutics Corp | Permeant delivery system and methods for use thereof |
JP4704829B2 (en) * | 2005-07-15 | 2011-06-22 | ニプロパッチ株式会社 | Patch and patch package |
CA2629046C (en) * | 2005-12-13 | 2014-04-08 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
TW200800223A (en) * | 2005-12-21 | 2008-01-01 | Shire Pharmaceuticals Inc | Transdermal delivery of meptazinol |
US7740879B2 (en) * | 2006-01-17 | 2010-06-22 | Harrogate Holdings | Abuse resistant transdermal drug delivery patch |
EP1986618A2 (en) * | 2006-02-13 | 2008-11-05 | Aveva Drug Delivery Systems, Inc. | Adhesive preparation comprising sufentanil and methods of using the same |
CN101454007B (en) | 2006-07-14 | 2011-04-13 | 久光制药株式会社 | Adhesive |
RS54764B1 (en) | 2006-07-21 | 2016-10-31 | Biodelivery Sciences Int Inc | Transmucosal delivery devices with enhanced uptake |
JP2010501001A (en) * | 2006-08-14 | 2010-01-14 | シャイア ファーマシューティカルズ インコーポレイテッド | Transdermal delivery of meptazinol |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
HUE030803T2 (en) | 2008-05-09 | 2017-06-28 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
US20110165248A1 (en) * | 2008-09-18 | 2011-07-07 | Meridith Lee Machonis | Pharmaceutical dosage forms comprising poly(e-caprolactone) |
TWI541246B (en) | 2008-12-08 | 2016-07-11 | 歐陸斯迪公司 | Dihydroetorphine |
KR101738369B1 (en) | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | Hot-melt extruded controlled release dosage form |
RU2555531C2 (en) | 2009-07-22 | 2015-07-10 | Грюненталь Гмбх | Misuse protected dosage form for oxidation sensitive opioids |
US9579285B2 (en) | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
CA2795158C (en) * | 2010-04-02 | 2019-10-22 | Alltranz Inc. | Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists |
NZ700732A (en) | 2010-05-10 | 2015-08-28 | Euro Celtique Sa | Pharmaceutical compositions comprising hydromorphone and naloxone |
EP2568965A1 (en) | 2010-05-10 | 2013-03-20 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
WO2011141489A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
US20130240384A1 (en) * | 2010-08-18 | 2013-09-19 | Purdue Pharma L.P. | Vacuum Avoiding Packaging Systems and Methods Thereof |
AR082862A1 (en) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER |
EP2611426B1 (en) | 2010-09-02 | 2014-06-25 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
AR087359A1 (en) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | TEST ALTERATION TABLET PROVIDING IMMEDIATE RELEASE OF THE PHARMACO |
EA201400172A1 (en) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES |
CA3119258A1 (en) | 2011-08-18 | 2013-02-21 | Biodelivery Sciences International, Inc. | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
MX362357B (en) | 2012-04-18 | 2019-01-14 | Gruenenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form. |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
CA2882870C (en) * | 2012-08-24 | 2020-12-15 | Integurx Therapeutics, Llc | Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents |
TW201431572A (en) | 2012-12-21 | 2014-08-16 | Teikoku Pharma Usa Inc | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
WO2014145699A1 (en) * | 2013-03-15 | 2014-09-18 | New Jersey Institute Of Technology | System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process |
AR096439A1 (en) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES |
JP6445537B2 (en) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant dosage forms containing one or more particles |
GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
EA032465B1 (en) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof |
NZ719087A (en) | 2013-11-13 | 2017-12-22 | Euro Celtique Sa | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
AU2014356581C1 (en) | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
KR102226652B1 (en) * | 2014-01-22 | 2021-03-12 | 4피 테라퓨틱스 | Abuse and misuse deterrent transdermal systems |
AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
CA2949422A1 (en) | 2014-05-26 | 2015-12-03 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
WO2016100708A1 (en) * | 2014-12-19 | 2016-06-23 | 3M Innovative Properties Company | Transdermal drug delivery device including fentanyl |
US10010543B1 (en) | 2014-12-23 | 2018-07-03 | Barr Laboratories, Inc. | Transdermal dosage form |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
GB201513442D0 (en) * | 2015-07-30 | 2015-09-16 | Euro Celtique Sa | Transdermal patch |
JP2018526414A (en) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Protection against oral overdose with abuse-inhibiting immediate release formulations |
US20190015352A1 (en) * | 2017-07-14 | 2019-01-17 | Pendleton Brewster Wickersham | Applicators & Patches for Dermal & Transdermal Treatment Material & Drug Delivery, Methods of Making Them, & Methods of Use |
WO2020009685A1 (en) * | 2018-07-02 | 2020-01-09 | John Tang | Transdermal dosage form |
WO2020008366A1 (en) * | 2018-07-02 | 2020-01-09 | Clexio Biosciences Ltd. | Transdermal dosage form |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5066494A (en) * | 1987-07-09 | 1991-11-19 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system |
US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
WO1997004835A1 (en) * | 1995-07-28 | 1997-02-13 | Novartis Ag | Transdermal system |
WO2002087482A1 (en) * | 2001-05-01 | 2002-11-07 | Euro-Celtique | Abuse resistant opioid containing transdermal systems |
WO2003090729A1 (en) * | 2002-04-23 | 2003-11-06 | Alza Corporation | Transdermal analgesic systems with reduced abuse potential |
Family Cites Families (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1602344A (en) | 1924-01-09 | 1926-10-05 | Eagle Peter | Medicating compress |
US2807262A (en) | 1952-12-10 | 1957-09-24 | Robert B Lew | Perforated plastic adhesive tape bandage |
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US3966940A (en) | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
US4457933A (en) | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4539256A (en) | 1982-09-09 | 1985-09-03 | Minnesota Mining And Manufacturing Co. | Microporous sheet material, method of making and articles made therewith |
GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
DE3546830C2 (en) | 1984-07-23 | 1995-07-20 | Alza Corp | Device for delivering fentanyl across the skin |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
US4687481A (en) * | 1984-10-01 | 1987-08-18 | Biotek, Inc. | Transdermal drug delivery system |
US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
US4960467A (en) | 1985-02-11 | 1990-10-02 | The United States Of America As Represented By The Secretary Of The Army | Dermal substance collection device |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US4693776A (en) | 1985-05-16 | 1987-09-15 | Minnesota Mining And Manufacturing Company | Macromer reinforced pressure sensitive skin adhesive |
US4666441A (en) | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
US4743249A (en) * | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
US4954343A (en) | 1986-03-29 | 1990-09-04 | Nitto Electric Industrial Co., Ltd. | Dermal pharmaceutical preparations |
DE3634016A1 (en) * | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | AREA-BASED THERAPEUTIC SYSTEM, METHOD FOR THE PRODUCTION THEREOF AND ITS USE |
US5344656A (en) | 1986-09-12 | 1994-09-06 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US4908027A (en) | 1986-09-12 | 1990-03-13 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US4906463A (en) | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
US4917688A (en) | 1987-01-14 | 1990-04-17 | Nelson Research & Development Co. | Bandage for transdermal delivery of systemically-active drug |
US4822802A (en) | 1987-02-24 | 1989-04-18 | Alza Corporation | Method of fentanly administration for postoperative pain relief |
US4746515A (en) | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
JPH0696529B2 (en) | 1987-03-31 | 1994-11-30 | 積水化学工業株式会社 | Nitroglycerin patch and method for producing the same |
US5186939A (en) | 1987-04-23 | 1993-02-16 | Cygnus Therapeutic Systems | Laminated composite for transdermal administration of fentanyl |
US4879297A (en) | 1987-06-01 | 1989-11-07 | Warner-Lambert Company | Fatty acids and their small chain esters as penetration enhancers in aqueous systems |
US4788064A (en) | 1987-07-31 | 1988-11-29 | Warner-Lambert Company | Transdermal delivery system |
US4839174A (en) | 1987-10-05 | 1989-06-13 | Pharmetrix Corporation | Novel transdermal nicotine patch |
US4994267A (en) | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
EP0356382B1 (en) | 1988-08-02 | 1994-02-16 | Ciba-Geigy Ag | Multilayer plaster |
US5185329A (en) | 1988-08-30 | 1993-02-09 | Bristol-Myers Squibb Company | Method for treatment of substance addiction |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
US5176917A (en) * | 1989-03-15 | 1993-01-05 | Lts Lohmann | Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances |
US5053227A (en) | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
US5788983A (en) | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
US4978532A (en) | 1989-08-11 | 1990-12-18 | Pharmedic Co. | Dosage form for administration of dehydroepiandrosterone |
US5750136A (en) | 1989-11-03 | 1998-05-12 | Riker Laboratories, Inc. | Bioadhesive composition and patch |
US5750134A (en) | 1989-11-03 | 1998-05-12 | Riker Laboratories, Inc. | Bioadhesive composition and patch |
SE8904296D0 (en) | 1989-12-21 | 1989-12-21 | Pharmacia Ab | TRANSDERMAL SYSTEM |
US5032637A (en) | 1990-03-14 | 1991-07-16 | Adhesives Research Inc. | Water-inactivatable pressure sensitive adhesive |
US5149719A (en) | 1990-04-27 | 1992-09-22 | Minnesota Mining And Manufacturing Company | Composition for transdermal penetration of medicaments |
DE4020144A1 (en) | 1990-06-25 | 1992-01-09 | Lohmann Therapie Syst Lts | Patches for topical or transdermal drug delivery - with adhesive layer contg. polyacrylate adhesive and film former |
US5382246A (en) * | 1990-09-18 | 1995-01-17 | Koyo Disposable Goods Company | Disposable diaper |
GB9021674D0 (en) | 1990-10-05 | 1990-11-21 | Ethical Pharma Ltd | Transdermal device |
US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
US5981666A (en) | 1991-07-12 | 1999-11-09 | Adhesives Research, Inc. | Method for the production of a high performance pressure sensitive adhesive |
US5123900A (en) * | 1991-08-16 | 1992-06-23 | Bertek, Inc. | Moisture permeable double disk |
US5518734A (en) | 1991-09-25 | 1996-05-21 | Beta Pharmaceuticals Co. | Transdermal delivery system for estradiol and process for manufacturing said device |
US5705185A (en) | 1991-09-25 | 1998-01-06 | Beta Pharmaceuticals Co. | Transdermal delivery of estradiol and process for manufacturing said device |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5352516A (en) | 1992-01-31 | 1994-10-04 | Adhesives Research, Inc. | Water-inactivatable pressure sensitive adhesive |
US5756117A (en) | 1992-04-08 | 1998-05-26 | International Medical Asscociates, Inc. | Multidose transdermal drug delivery system |
US5264219A (en) | 1992-08-07 | 1993-11-23 | Minnesota Mining And Manufacturing Company | Transdermal drug delivery backing |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5462743A (en) * | 1992-10-30 | 1995-10-31 | Medipro Sciences Limited | Substance transfer system for topical application |
US5762952A (en) | 1993-04-27 | 1998-06-09 | Hercon Laboratories Corporation | Transdermal delivery of active drugs |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
JP3592715B2 (en) | 1993-10-29 | 2004-11-24 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Pressure sensitive adhesive with microstructured surface |
US5508367A (en) | 1993-11-29 | 1996-04-16 | Adhesives Research, Inc. | Water-soluble pressure sensitive adhesive |
US5395907A (en) | 1993-11-29 | 1995-03-07 | Adhesive Research, Inc. | Water-soluble pressure sensitive adhesive |
US5494680A (en) | 1993-12-08 | 1996-02-27 | Minnesota Mining And Manufacturing Company | Transdermal delivery device |
JPH07206710A (en) | 1994-01-21 | 1995-08-08 | Nitto Denko Corp | Tape preparation for transcutaneous administration |
US5536263A (en) | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
GB9409281D0 (en) * | 1994-05-10 | 1994-06-29 | Svedman Paul | Transdermal device |
US5589480A (en) | 1994-08-17 | 1996-12-31 | Elkhoury; George F. | Topical application of opioid analgesic drugs such as morphine |
JP3908795B2 (en) | 1994-11-29 | 2007-04-25 | 久光製薬株式会社 | Ketotifen-containing transdermal preparation |
US6063838A (en) | 1995-02-16 | 2000-05-16 | 3M Innovative Properties Company | Blended pressure-sensitive adhesives |
US5573778A (en) | 1995-03-17 | 1996-11-12 | Adhesives Research, Inc. | Drug flux enhancer-tolerant pressure sensitive adhesive composition |
US5866143A (en) | 1995-03-24 | 1999-02-02 | El Khoury And Stein, Ltd. | Topical application of opioid drugs such as morphine for relief of itching and skin disease |
US6093419A (en) | 1995-06-07 | 2000-07-25 | Lectec Corporation | Compliance verification method and device in compulsory drug administration |
US5840327A (en) * | 1995-08-21 | 1998-11-24 | Alza Corporation | Transdermal drug delivery device having enhanced adhesion |
US5733571A (en) | 1995-12-08 | 1998-03-31 | Euro-Celtique, S.A. | Transdermal patch for comparative evaluations |
US5703169A (en) | 1996-01-24 | 1997-12-30 | Adhesives Research, Inc. | Non-corrosive, low volatiles-containing pressure sensitive adhesive |
ES2168610T3 (en) | 1996-03-12 | 2002-06-16 | Alza Corp | COMPOSITION AND GALENIC FORM CONTAINING AN OPIOID ANTAGONIST. |
HUP9902673A3 (en) | 1996-03-25 | 2001-04-28 | Lohmann Therapie Syst Lts | Transdermal therapeutic system with small application-area thickness and great flexibility, and production process |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
US5783583A (en) | 1996-04-12 | 1998-07-21 | Simon; David Lew | 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification |
US6271240B1 (en) | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
US6365178B1 (en) * | 1996-09-06 | 2002-04-02 | Watson Pharmaceuticals, Inc. | Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions |
CA2264687C (en) | 1996-10-24 | 2006-04-25 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
EP0971662A1 (en) | 1996-10-30 | 2000-01-19 | TheraTech, Inc. | Fatty acid esters of glycolic acid and its salts as permeation enhancers |
US6787149B1 (en) | 1996-12-12 | 2004-09-07 | El Khoury And Stein Ltd. | Topical application of opioid analgesic drugs such as morphine |
DE19653606A1 (en) | 1996-12-20 | 1998-06-25 | Roehm Gmbh | Adhesive and binder made from (meth) acrylate polymer, organic acid and plasticizer |
DE19653605C2 (en) | 1996-12-20 | 2002-11-28 | Roehm Gmbh | Adhesives and binders for dermal or transdermal therapy systems and their use for producing a transdermal therapy system |
DE19654468C1 (en) | 1996-12-27 | 1998-01-22 | Lohmann Therapie Syst Lts | Flexible dermal or transdermal plaster for drug or cosmetic release |
US5951999A (en) | 1997-02-21 | 1999-09-14 | Adhesives Research, Inc. | Transdermal pressure sensitive adhesive drug delivery system |
US6239228B1 (en) | 1997-02-21 | 2001-05-29 | Adhesives Research, Inc. | Pressure sensitive adhesive containing macromer having repeat hydrophilic moieties |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
ATE293960T1 (en) | 1997-02-28 | 2005-05-15 | Minnesota Mining & Mfg | TRANSDERMAL DEVICE FOR ADMINISTRATION OF TESTOSTERONE |
US6018092A (en) | 1997-03-04 | 2000-01-25 | 3M Innovative Properties Company | Medical adhesive bandage, delivery system and method |
US5804215A (en) | 1997-03-21 | 1998-09-08 | L. Perrigo Company | Transdermal patch disposal system and method |
US5976547A (en) | 1997-04-22 | 1999-11-02 | Niblick Pharmaceuticals, Inc. | Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery |
US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
IT1294748B1 (en) | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | FORMULATION FOR A TRANSDERMAL DEVICE |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
PT1685839E (en) | 1997-12-22 | 2013-07-08 | Euro Celtique Sa | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist |
CA2314896C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | A method of preventing abuse of opioid dosage forms |
US6143278A (en) | 1998-02-23 | 2000-11-07 | Elkhoury; George F. | Topical application of opioid analgesic drugs such as morphine |
US6193996B1 (en) | 1998-04-02 | 2001-02-27 | 3M Innovative Properties Company | Device for the transdermal delivery of diclofenac |
US6294038B1 (en) * | 1998-08-05 | 2001-09-25 | Advanced Label Systems, Inc. | Apparatus and method for applying linerless labels |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
US6159497A (en) | 1998-10-30 | 2000-12-12 | Noven Pharmaceuticals, Inc. | Patch applicator |
US6129929A (en) | 1998-10-30 | 2000-10-10 | Noven Pharmaceuticals, Inc. | Patch applicator |
US6136807A (en) | 1998-11-10 | 2000-10-24 | 3M Innovative Properties Company | Composition for the transdermal delivery of lerisetron |
US6348210B1 (en) | 1998-11-13 | 2002-02-19 | Alza Corporation | Methods for transdermal drug administration |
US6183770B1 (en) | 1999-04-15 | 2001-02-06 | Acutek International | Carrier patch for the delivery of agents to the skin |
US20020110585A1 (en) * | 1999-11-30 | 2002-08-15 | Godbey Kristin J. | Patch therapeutic agent delivery device having texturized backing |
HUP0204163A2 (en) | 2000-02-08 | 2003-04-28 | Euro-Celtique S.A. | Controlled-release composition containing opioid agonist and antagonist and process for its preparation |
US20020119187A1 (en) | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
US20020198215A1 (en) | 2000-10-23 | 2002-12-26 | Lino Tavares | Terazosin transdermal device and methods |
US7018649B2 (en) | 2000-10-23 | 2006-03-28 | Euro-Celtique, S.A. | Felodipine transdermal device and methods |
ATE460928T1 (en) | 2000-10-23 | 2010-04-15 | Euro Celtique Sa | TRANSDERMAL SYSTEM FOR ADMINISTRATION OF LORATADINE AND USE THEREOF |
GB0026137D0 (en) | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
CZ307857B6 (en) | 2001-03-16 | 2019-07-03 | Alza Corporation | A transdermal patch for administering fentanyl or an analogue of it |
ATE459317T1 (en) | 2001-04-23 | 2010-03-15 | Euro Celtique Sa | DISPOSAL SYSTEM FOR TRANSDERMAL DOSAGE FORMS |
US20030065002A1 (en) | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
DE60216078T2 (en) | 2001-05-11 | 2007-07-05 | Endo Pharmaceuticals Inc. | OPIOID CONTAINING ARZNEIFORM AGAINST MISUSE |
PT1390866E (en) | 2001-05-22 | 2010-04-26 | Euro Celtique Sa | Container and method for dispensing transdermal dosage forms |
AU2002313628A1 (en) | 2001-05-22 | 2002-12-03 | Euro-Celtique | Tamper resistant oral dosage form |
US20030064122A1 (en) | 2001-05-23 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse resistant pharmaceutical composition containing capsaicin |
PT1416842E (en) | 2001-07-18 | 2009-03-31 | Euro Celtique Sa | Pharmaceutical combinations of oxycodone and naloxone |
PL367427A1 (en) | 2001-08-06 | 2005-02-21 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
US6893655B2 (en) | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
ATE364561T1 (en) | 2001-10-22 | 2007-07-15 | 3M Innovative Properties Co | PACKAGING FOR TRANSDERMAL/TRANSMUCOSAL PLASTERS |
CA2469200A1 (en) | 2001-12-17 | 2003-06-26 | Aryx Therapeutics | Analgesic delivery systems and methods of use |
US6838078B2 (en) | 2002-01-16 | 2005-01-04 | 3M Innovative Properties Company | Film-forming compositions and methods |
US20040033253A1 (en) | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
RU2209062C1 (en) | 2002-03-19 | 2003-07-27 | Институт физиологии им. И.П.Павлова РАН | Substance of sedative action |
ATE394097T1 (en) | 2002-03-20 | 2008-05-15 | Euro Celtique Sa | METHOD OF ADMINISTRATION OF BUPRENORPHINE FOR THE TREATMENT OF DEPRESSION |
AU2003251482A1 (en) | 2002-06-10 | 2003-12-22 | Euro-Celtique, S.A. | Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
US20050191340A1 (en) | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
DE60326354D1 (en) * | 2002-08-20 | 2009-04-09 | Euro Celtique Sa | TRANSDERMAL DOSAGE FORM CONTAINING AN ACTIVE SUBSTANCE AND AN ANTAGONIST IN FREE BASE AND SALT FORM |
US20040109886A1 (en) * | 2002-08-27 | 2004-06-10 | Larry Rigby | Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent |
IL166687A0 (en) * | 2002-08-30 | 2006-01-15 | Alza Corp | Embossable and writable multilaminate backing construction |
US7202259B2 (en) | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
ES2310262T3 (en) | 2002-12-13 | 2009-01-01 | Euro-Celtique S.A. | DOSAGE REGIME OF TRANSDERMIC BRUPRENORPHINE FOR ANALGESIA. |
US7413748B2 (en) | 2002-12-13 | 2008-08-19 | Purdue Pharma L.P. | Transdermal buprenorphine to treat pain in sickle cell crisis |
US20040202708A1 (en) | 2003-04-14 | 2004-10-14 | 3M Innovative Properties Company | Transdermal drug delivery device with translucent inorganic barrier layer |
US20040219195A1 (en) | 2003-04-30 | 2004-11-04 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
US7182955B2 (en) | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
CL2004000927A1 (en) | 2003-04-30 | 2005-01-28 | Purdue Pharma Lp | TRANSDERMAL DOSAGE FORM THAT INCLUDES AN ACTIVE AGENT, A NEXT SURFACE AND A DISTAL SURFACE. |
US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US20040219198A1 (en) | 2003-05-01 | 2004-11-04 | 3M Innovative Properties Company | Transdermal drug delivery device with multilayer backing |
-
2004
- 2004-04-30 CL CL200400927A patent/CL2004000927A1/en unknown
- 2004-04-30 AR ARP040101494A patent/AR047936A1/en not_active Application Discontinuation
- 2004-04-30 MY MYPI20041622A patent/MY141815A/en unknown
- 2004-04-30 UA UAA200511386A patent/UA82880C2/en unknown
- 2004-04-30 EA EA200501702A patent/EA009623B1/en not_active IP Right Cessation
- 2004-04-30 US US10/835,535 patent/US8778382B2/en active Active
- 2004-04-30 TW TW093112241A patent/TWI350186B/en not_active IP Right Cessation
- 2004-04-30 MX MXPA05011703A patent/MXPA05011703A/en active IP Right Grant
- 2004-04-30 BR BRPI0409945-1A patent/BRPI0409945A/en not_active Application Discontinuation
- 2004-04-30 EP EP10011795A patent/EP2319505A1/en not_active Withdrawn
- 2004-04-30 RS YUP-2005/0812A patent/RS20050812A/en unknown
- 2004-04-30 PE PE2004000434A patent/PE20050146A1/en not_active Application Discontinuation
- 2004-04-30 JP JP2006514265A patent/JP5048324B2/en active Active
- 2004-04-30 WO PCT/US2004/013810 patent/WO2004098567A2/en active Application Filing
- 2004-04-30 ME MEP-2008-492A patent/ME00276B/en unknown
- 2004-04-30 PE PE2008000867A patent/PE20081297A1/en not_active Application Discontinuation
- 2004-04-30 EP EP04751268.6A patent/EP1641441B1/en active Active
- 2004-04-30 EP EP10011794A patent/EP2316440A1/en not_active Withdrawn
- 2004-04-30 AU AU2004235794A patent/AU2004235794B8/en active Active
- 2004-04-30 NZ NZ542969A patent/NZ542969A/en not_active IP Right Cessation
- 2004-04-30 CA CA2522529A patent/CA2522529C/en active Active
- 2004-04-30 KR KR1020057020592A patent/KR101159828B1/en active IP Right Grant
-
2005
- 2005-10-04 IS IS8060A patent/IS2935B/en unknown
- 2005-10-12 NO NO20054682A patent/NO332157B1/en not_active IP Right Cessation
- 2005-11-29 EC EC2005006191A patent/ECSP056191A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5066494A (en) * | 1987-07-09 | 1991-11-19 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system |
US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
WO1997004835A1 (en) * | 1995-07-28 | 1997-02-13 | Novartis Ag | Transdermal system |
WO2002087482A1 (en) * | 2001-05-01 | 2002-11-07 | Euro-Celtique | Abuse resistant opioid containing transdermal systems |
WO2003090729A1 (en) * | 2002-04-23 | 2003-11-06 | Alza Corporation | Transdermal analgesic systems with reduced abuse potential |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004098567A3 (en) | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer | |
WO2004064769A3 (en) | Methods for making and using topical delivery agents | |
WO2007006043A3 (en) | Medical devices with machined layers for controlled communication with underlying regions | |
WO2007133518A3 (en) | Modulating agents for antimicrobial coatings | |
NO20054681L (en) | Pharmaceutical products | |
WO2008036549A3 (en) | Medical devices | |
WO2004073623A3 (en) | Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions | |
WO2005117870A3 (en) | Combination of proton pump inhibitor, buffering agent, and prokinetic agent | |
WO2006007448A3 (en) | Pharmaceutical co-crystal compositions and related methods of use | |
WO2006055603A3 (en) | Injectable nanoparticulate olanzapine formulations | |
WO2005011586A3 (en) | Treatment and preventi0n of cardiovascular events | |
WO2007054573A3 (en) | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and egfr inhibitors or pyrimidine analogues | |
WO2004009616A3 (en) | Ghrelin analogs | |
WO2007146231A3 (en) | Solvent systems for coating medical devices | |
WO2005044199A3 (en) | Combination of proton pump inhibitor and sleep aid | |
WO2002067895A3 (en) | Implant dosage form and use thereof for the delivery of a cholesterol lowering agent | |
WO2005007115A3 (en) | Pharmaceutical composition for inhibiting acid secretion | |
WO2006023814A3 (en) | Effervescent composition including a grape-derived component | |
WO2004100926A3 (en) | Delivery of agents using hydrolyzable leaving groups | |
WO2004098568A3 (en) | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer | |
WO2006060542A3 (en) | Formulations of substituted benzoxazoles | |
WO2006131401A3 (en) | Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent | |
WO2003082926A3 (en) | Antimicrobial polymer conjugates | |
WO2004073615A3 (en) | Deazaflavin compounds and methods of use thereof | |
WO2005053394A3 (en) | Synergistic insecticide mixtures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-2005/0812 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-501742 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/07862 Country of ref document: ZA Ref document number: 200507862 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004235794 Country of ref document: AU Ref document number: CR2005-008030 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2522529 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 542969 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4747/DELNP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004235794 Country of ref document: AU Date of ref document: 20040430 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004235794 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057020592 Country of ref document: KR Ref document number: 2006514265 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 171665 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/011703 Country of ref document: MX Ref document number: 2004811691X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004751268 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200501702 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05121481 Country of ref document: CO |
|
WWP | Wipo information: published in national office |
Ref document number: 2004751268 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0409945 Country of ref document: BR |